Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

SHANGHAI, Feb 24 (Reuters) - Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...

Pfizer (PFE) stock is in focus as the FDA grants full approval for its colorectal cancer drug Braftovi, developed with Ono Pharmaceutical (OPHLF). Read more here.

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...

More recently, Pfizer splashed out $150 million upfront—and put up hundreds of millions more in potential milestones—to acquire worldwide rights to a GLP-1 agonist dubbed YP05002 from Yao Pharma, a ...

Ecnoglutide is one of a growing number of GLP-1 drugs in Chinese market. Sciwind gained approved for it to be used in China ...

Pfizer has acquired exclusive rights to commercialize an obesity therapy in China in a deal worth up to $495 million.

Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for its hemophilia therapy, Hympavzi. The New ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration may revoke authorization for Pfizer’s COVID-19 vaccine for healthy children under age 5, the ...